Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study
In patients with GAD and inadequate response to SSRI/SNRI, adjunct quetiapine XR did not show a statistically significant effect for the primary endpoint at Week 8, although some secondary endpoints were statistically significant versus placebo. Quetiapine XR was generally well tolerated.
Authors
- Irina Mezhebovsky
- Sanjeev Pathak (ORCID: https://orcid.org/0000-0001-5842-690X)
- Fahua She
- Todd Leathers
- Sarah Atkinson (ORCID: https://orcid.org/0000-0001-6971-7112)
- Arifulla Khan
Institutions
- Northwest Clinical Research Center (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4062
- Citations
- 3
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00